P.J. Haley
total strong prescriptions became the prescriptions Chris. in discuss and you number being in for very TKI Thank performance detail today CABOMETYX pleased In quarter. new to RCC built for this RCC. in leading the I'm QX on you position the CABOMETYX of of TRx one in with first TKI the in
prescriptions metrics of off across the these and variety in an a CABOMETYX in growth of business, in quarter-over-quarter start driven and and positive In the HCC. saw in remarks. touch expansion demand new year-over-year is RCC of XX% trends Patient encouraging we Additionally, and on I CABOMETYX the QX of by terms was will demand, prescriber and grew by approval X% base. launch this that HCC to both
the relative growth new New QX equally Prescriptions or by The in up XX% fourth driven NRx to XXXX. of prescriptions HCC. in and were was RCC by QX quarter in
into We from tumor CABOMETYX for for underscores types detail to franchise go both the and more momentarily. are indicated. each both growth for demand parts see new is of the coming pleased which of and new in healthy the will This prescriptions I fundamentals
as community XXXX. prescribers CABOMETYX net and both about HCC, year-over-year $XXX XX% new Additionally, representing X.X% to an million, revenue the as XX% grew year-over-year grew new HCC. prescribers This driven base growth for prescriber and was and quarter-over-quarter by of well RCC academic increase quarter-over-quarter. within XX% by from
increasingly Furthermore, to RCC industry more market RCC that mentioned, year oral inventory in in was on revenue appears Chris the CABOMETYX. to QX quarters build. built will by to for As continues inhibitor as now of of now of is which the range QX be low-end PHS for kinase historically drawdown two I turn the across net hole the utilization, expenditures, a following that well. Medicare specifics we case inventory and tyrosine last increased the inventory successive increased of donut marketplace, impacted become Inventory observed the competitive. was and
the PD-X better we To IQVIA sense recently the axitinib setting. competitive QX, sunitinib, TKI and We in the the of our have comprised of of combination dynamics approved CABOMETYX. get pazopanib, market inhibitor, analyzed TKI in for anticipated and for oral combinations approval first long RCC very through pembrolizumab evolving data and was line axitinib a TKI RCC the
analysis the of total As share XX%. you available data, [indiscernible] in share publicly surpassing, QX three can for became point of CABOMETYX market prescriptions this see from in TKI leading gaining TRX
and X% We CABOMETYX share last in continued significant to progress despite marketplace. relative TRX XXXX. point are the increase of relative quarter the a in to pleased that competitive QX a This growth X% of QX in represents to grow rate
these RCC Additionally, became that market. prescriptions number TKI in the the show one data CABOMETYX for total
The continues PD-X the RCC NRx after of in patients progress. to prescriptions choose QX CABOMETYX in leading trend higher their growth Turning surveyed indicate that Market in quarters would RCC second TKI became whether to growth as into to or increased rate a therapeutic have at who have for sequencing options have momentum the continue number continue is on Also IQVIA about growth who combination, you have TKI. the this key as in and CABOMETYX since CABOMETYX the the has will The received QX. coming who ICI QX the on opportunity to vast many heading cabo to April, NivoIpi choice approval may will to is increased of combination either and Q-over-Q. sequence. of approximately majority the to good the share first relative QX. largely to in CABOMETYX pembro/axi. patients NivoIpi as NivoIpi of market Both RCC patient receive were and X% the NRx line CABOMETYX market again the opinion combination NRx of trend QX a XX% NRx, the QX followed feel driven therapeutic to continue second-line QX expect combination to in we frontline well we be recall XX%. increase therapy patients by the to cabo’s patients showing in in option in of be sequencing encouraging, progressed new it placed progress impact, brand is ops. XX% the research Most for line an rates to leaders of CABOMETYX CABOMETYX gradual QX ICI yet ICI by line of that According QX. this or positioned well on relative grew that followed TRx is by line there The patients treatment. in patients are and these outpacing has the second the in treatment CABOMETYX new business first NivoIpi the in from stable progressed have their Furthermore, strong market data was and is share of
suggest who impact captured NivoIpi mentioned. brand consistent IQVIA just research from data of QX with share in CABOMETYX the fact, on market patients our vast of that progressed In market majority
of across clinical utilization lines We see broad continue and academic groups. settings, and risk to community therapy
flow data, patient the in and to we expect grow the CABOMETYX dynamics continue the strength demand to Given of XXXX. RCC
also addition In growth and continued a cabozantinib in in for to CABOMETYX in the franchise. excited forth indication momentum to newly type representing indication of RCC, we're the received drive the tumor HCC third
Our executing for the team days are in progress upon line the early our launch, still approval the XX the and metrics on the January HCC expectations. on and exceeding indicate we're receiving second that immediately of We're launch we but pleased with indication the made. key began
that to some As with we for HCC external new in patients. coming for the consistent years. will research these market as a market have that therapies This stated be will is grow need available become built is HCC the which time, market indicates
cabo HCC. CABOMETYX consistent that research we're of seeing with are the HCC the CABOMETYX market significant these market market collective will of and majority encouraging to share Our the cabo indicates is and already the patients indicate aware already seeing choice as taking prescribe approved in awareness as from consistent the its we trends of in indicates market observations regorafenib. relative prescriptions in data, of viewed initial If terms to pretreated and both that new achieving with research physicians this demand. be Initial TKIs CELESTIAL labeling. other intend HCC TKI is We in the they
we the of I new As half of my demand seeing in earlier and prescriptions in are approximately HCC remarks, in first cabo’s half growth contribute growth mentioned brand's quarter. to the
pleased physician regards a type. are metrics. are survival is fact to on seems indication additional tumor We and the with the brand. HCC these cabo that for other among RCC in Based a benefit the CABOMETYX that of in The and CABOMETYX second to competence both community demonstrated growing generated have HCC synergies
HCC for but force account the HCC facilitated and increased productive prescribers the access our meaningful not approval of increased interactions Importantly, discussions well. only number sales with as has discussions as and RCC
fact, voice and In early share potential, has sales This the data to the in is Well, in approach of HCC market. our specific the and preapproval RCC covered days, RCC we leading our validating leading HCC of share approximately on plus share combined line immediately the CABOMETYX RCC footprint of began market. the following calling external maintaining voice market HCC approval. the voice XX% remaining prescribers while second strategic
and CABOMETYX community HCC. with community familiarity aiding and uptake oncology Our is physician the established within footprint
Our HCC cabo an be would had This increased is for largely playing written of the CABOMETYX interest HCC, the academic and experience and physician RCC. prescribers using there in in is prescribing XX% are in QX XX% market other had previously that cabo based. research approximately out had indicated market previous the if
the segments both for pleased the We of community in academic this market. and uptake to see HCC are
patients number with patients overall other program is The now results our with customers and and in building future development RCC continues patients We TKI gives momentum the are from strive in the RCC, and and cancers. indications demand on augment to potential cabozantinib prescription and the prescribed HCC. forward CABOMETYX. of more as brand options one more as many help in perception now they and terms look difficult-to-treat we in HCC HCC CABOMETYX to QX of new this could and the that to CABOMETYX but approval pleased expands. HCC, the grew positive benefit RCC RCC QX both also of believe
continue turn to Gisela. and focused patient the eligible compete the day the motivated CABOMETYX every Our every bring as of to franchise. team With call to we I'll to build over that, benefit to is